A study published in the Journal of the American Medical Association found that metformin used as an adjunct to insulin therapy for patients with type 2 or gestational diabetes does not reduce the odds of neonatal adverse outcomes. The research involved pregnant adults with type 2 diabetes or diabetes diagnosed before 23 weeks of pregnancy, and participants were randomly assigned to receive either metformin or a placebo in addition to insulin therapy. The study found that there was no significant difference in neonatal complications between the metformin and placebo groups, with the exception of large for gestational age infants. The researchers suggested further investigation into the effects of metformin and insulin therapy on neonatal outcomes.
Source link
Metformin Plus Insulin Therapy Does Not Reduce Neonatal Adverse Outcomes
